DADC
HRMY icon

D.A. Davidson & Co’s Harmony Biosciences HRMY Stock Holding History

D.A. Davidson & Co’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,944
Closed -$1.08M – 1450
2024
Q3 		$1.08M Sell
26,944
-93
-0.3% -$3.27K 0.01% 742
2024
Q2 		$816K Hold
27,037
– – 0.01% 799
2024
Q1 		$908K Sell
27,037
-16
-0.1% -$514 0.01% 771
2023
Q4 		$874K Sell
27,053
-1,876
-6% -$52.4K 0.01% 753
2023
Q3 		$948K Sell
28,929
-781
-3% -$27.1K 0.01% 691
2023
Q2 		$1.05M Sell
29,710
-664
-2% -$22.9K 0.01% 673
2023
Q1 		$992K Sell
30,374
-1,316
-4% -$59.9K 0.01% 677
2022
Q4 		$1.75M Sell
31,690
-102
-0.3% -$5.61K 0.02% 475
2022
Q3 		$1.41M Sell
31,792
-802
-2% -$39.1K 0.02% 490
2022
Q2 		$1.59M Sell
32,594
-475
-1% -$21.4K 0.02% 481
2022
Q1 		$1.61M Buy
+33,069
New +$1.35M 0.02% 512

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.A. Davidson & Co's HRMY Position: Q4 2024 in Review

D.A. Davidson & Co sold out of Harmony Biosciences (HRMY) in Q4 2024, closing a stake of 26,944 shares — an estimated $1.08M sold.

D.A. Davidson & Co first reported a position in HRMY in Q1 2022 and held it in 11 quarters. The position peaked at $1.75M in Q4 2022. 247 funds tracked by Wall St. Rank hold HRMY as of Q4 2024.

  • D.A. Davidson & Co reported no remaining Harmony Biosciences position as of Q4 2024 after selling out during the quarter.
  • D.A. Davidson & Co sold 26,944 Harmony Biosciences shares in Q4 2024, an estimated $1.08M.
  • D.A. Davidson & Co first reported a position in Harmony Biosciences in Q1 2022 and held it in 11 quarters.
  • D.A. Davidson & Co's Harmony Biosciences position peaked at $1.75M in Q4 2022.
  • 247 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2024.

Based on D.A. Davidson & Co's 13F filing for Q4 2024, filed 31 Jan 2025.